RTP startup eyes big raise to advance its treatments for depression


A small company with ties to Duke University is raising capital to advance the development of new treatments for people who don't respond to first-line antidepressants.

Previous HamptonRock Partners explain why the timing was right to expand
Next Brixey & Meyer Capital sells portfolio company Guardian Access Solutions to Dallas PE firm